Financing ·
China SXT Pharmaceuticals raises $12M in registered direct offering of units at $1.50
SXTCChina SXT Pharmaceuticals, Inc.
China SXT Pharmaceuticals, Inc. closed a registered direct offering on October 9, 2026, selling 8,000,000 units to investors for gross proceeds of approximately $12,000,000. Each unit consists of one Class A ordinary share or pre-funded warrant and one ordinary warrant exercisable at $2.75 per share until October 9, 2027. The company engaged Univest Securities, LLC as placement agent for a 7% fee plus expenses. The offering includes an over-allotment option to raise an additional $12,000,000 within 30 days of closing. China SXT Pharmaceuticals, Inc. operates in the pharmaceutical industry.